Arbutus Biopharma Corporation (ABUS)
NASDAQ: ABUS · Real-Time Price · USD
4.150
-0.130 (-3.04%)
Apr 28, 2026, 4:00 PM EDT - Market closed
Arbutus Biopharma Balance Sheet
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
Fiscal Year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | 2020 - 2016 |
|---|---|---|---|---|---|---|
Period Ending | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | 2020 - 2016 |
| Cash & Equivalents | 18.01 | 36.33 | 26.29 | 30.78 | 109.28 | Upgrade
|
| Short-Term Investments | 73.46 | 86.29 | 99.72 | 116.14 | 46.04 | Upgrade
|
| Cash & Short-Term Investments | 91.47 | 122.62 | 126 | 146.91 | 155.32 | Upgrade
|
| Cash Growth | -25.41% | -2.68% | -14.23% | -5.41% | 26.00% | Upgrade
|
| Accounts Receivable | 1.45 | 2.41 | 1.78 | 1.35 | 0.9 | Upgrade
|
| Other Receivables | 0.3 | 0.3 | 0.6 | - | - | Upgrade
|
| Receivables | 1.75 | 2.71 | 2.38 | 1.35 | 0.9 | Upgrade
|
| Prepaid Expenses | 1.24 | 1.98 | 3.65 | 2.87 | 4.45 | Upgrade
|
| Total Current Assets | 94.46 | 127.32 | 132.03 | 151.14 | 160.66 | Upgrade
|
| Property, Plant & Equipment | 0.03 | 4.36 | 6.09 | 6.81 | 8.08 | Upgrade
|
| Long-Term Investments | - | - | 6.28 | 37.36 | 35.69 | Upgrade
|
| Other Long-Term Assets | 0.13 | 0.03 | - | 0.1 | 0.06 | Upgrade
|
| Total Assets | 94.62 | 131.71 | 144.4 | 195.42 | 204.49 | Upgrade
|
| Accounts Payable | 1.17 | 2.32 | 3.22 | 3.52 | 3.17 | Upgrade
|
| Accrued Expenses | 3.65 | 5.25 | 7.05 | 12.51 | 7.66 | Upgrade
|
| Current Portion of Leases | 0.55 | 0.48 | 0.43 | 0.37 | 0.38 | Upgrade
|
| Current Unearned Revenue | - | 7.57 | 11.79 | 16.46 | - | Upgrade
|
| Other Current Liabilities | 0.64 | - | - | - | - | Upgrade
|
| Total Current Liabilities | 6.01 | 15.62 | 22.49 | 32.86 | 11.22 | Upgrade
|
| Long-Term Debt | 3.44 | 4.83 | 6.95 | 10.37 | 16.3 | Upgrade
|
| Long-Term Leases | 0.2 | 0.81 | 1.34 | 1.82 | 2.23 | Upgrade
|
| Long-Term Unearned Revenue | - | 2.86 | - | 6 | - | Upgrade
|
| Other Long-Term Liabilities | 8.4 | 10.23 | 7.6 | 7.53 | 5.3 | Upgrade
|
| Total Liabilities | 18.04 | 34.34 | 38.38 | 58.57 | 35.05 | Upgrade
|
| Common Stock | 1,421 | 1,410 | 1,350 | 1,319 | 1,287 | Upgrade
|
| Additional Paid-In Capital | 83.32 | 82.05 | 81.27 | 72.41 | 65.49 | Upgrade
|
| Retained Earnings | -1,380 | -1,347 | -1,277 | -1,204 | -1,134 | Upgrade
|
| Comprehensive Income & Other | -48.1 | -48.14 | -48.42 | -50.49 | -48.34 | Upgrade
|
| Total Common Equity | 76.58 | 97.37 | 106.02 | 136.85 | 169.44 | Upgrade
|
| Shareholders' Equity | 76.58 | 97.37 | 106.02 | 136.85 | 169.44 | Upgrade
|
| Total Liabilities & Equity | 94.62 | 131.71 | 144.4 | 195.42 | 204.49 | Upgrade
|
| Total Debt | 4.19 | 6.12 | 8.72 | 12.55 | 18.91 | Upgrade
|
| Net Cash (Debt) | 87.28 | 116.51 | 123.57 | 171.72 | 172.1 | Upgrade
|
| Net Cash Growth | -25.08% | -5.71% | -28.04% | -0.22% | 70.85% | Upgrade
|
| Net Cash Per Share | 0.46 | 0.63 | 0.74 | 1.14 | 1.62 | Upgrade
|
| Filing Date Shares Outstanding | 195.48 | 191.48 | 179.49 | 162.57 | 148.64 | Upgrade
|
| Total Common Shares Outstanding | 192.53 | 189.96 | 169.87 | 157.46 | 144.99 | Upgrade
|
| Working Capital | 88.45 | 111.7 | 109.54 | 118.28 | 149.44 | Upgrade
|
| Book Value Per Share | 0.40 | 0.51 | 0.62 | 0.87 | 1.17 | Upgrade
|
| Tangible Book Value | 76.58 | 97.37 | 106.02 | 136.85 | 169.44 | Upgrade
|
| Tangible Book Value Per Share | 0.40 | 0.51 | 0.62 | 0.87 | 1.17 | Upgrade
|
| Machinery | 0.25 | 7.72 | 7.98 | 7.28 | 6.79 | Upgrade
|
| Leasehold Improvements | - | 8.59 | 8.59 | 8.59 | 8.56 | Upgrade
|
Source: S&P Capital IQ. Standard template. Financial Sources.